newsfilter
← Latest News
Business Wire·

Immunome Reports Full Year 2025 Financial Results and Provides Business Update

New Drug Application submission for varegacestat in patients with desmoid tumors planned for 2Q 2026 IM-1021 Phase 1 ongoing with initial data expected in 2026 Three IND submissions for solid tumor-targeted ADC